Abstract
Toxoplasma gondii is a zoonotic parasite that infects the brain of humans and causes cerebral toxoplasmosis. The recommended drugs for the treatment or prophylaxis of toxoplasmosis are pyrimethamine (PY) and sulfadiazine (SZ), which have serious side effects. Other drugs available for toxoplasmosis are poorly tolerated. Dihydroquinine (DHQ) is a compound closely related to quinine-based drugs that have been shown to inhibit Plasmodium falciparum and Plasmodium berghei in addition to its anti-arrhythmia properties. However, little is known about the effect of DHQ in T. gondii growth and its mechanism of action in vitro. In this study, we report the anti-Toxoplasma and anti-invasion properties of DHQ. DHQ significantly inhibited T. gondii tachyzoite growth with IC50s values of 0.63, 0.67, and 0.00137 µM at 24, 48, and 72 h, respectively. Under similar conditions, SZ and PY, considered as the gold standard drugs for the treatment of toxoplasmosis, had IC50s values of 1.29, 1.55, and 0.95 and 3.19, 3.52, and 2.42 µM, respectively. The rapid dose-dependent inhibition of T. gondii tachyzoites by DHQ compared to the standard drugs (SZ and PY) indicates that DHQ has high selective parasiticidal effects against tachyzoite proliferation. Remarkably, DHQ had an excellent selectivity index (SI) of 149- and 357-fold compared to 24- and 143-fold for PY and SZ, respectively, using fibroblast cells. In addition, DHQ disrupted T. gondii tachyzoite mitochondrial membrane potential and adenosine triphosphate (ATP) production and elicited high reactive oxygen species (ROS) generation. Taking all these findings together, DHQ promises to be an effective and safe lead for the treatment of toxoplasmosis.
Introduction
Toxoplasma gondii is an obligate intracellular parasite that causes toxoplasmosis. Globally, between 30% and 50% of humans (Pappas et al., 2009; Flegr et al., 2014) and 35% and 76% of wild and domestic felids are infected with T. gondii (Montazeri et al., 2020). According to the Centers for Disease Control and Prevention (CDC), T. gondii is one of the leading causes of foodborne-related illness in the United States (CDC, 2021). Additionally, it has been reported that T. gondii infections negatively impact the US economy (Ben-Harari and Connolly, 2019).
Importantly, studies have shown a positive correlation in molecular signatures between suicide rate, schizophrenia, Alzheimer’s and Parkinson’s diseases, and T. gondii infections (Kamerkar and Davis, 2012; Gajewski et al., 2013; Ngô et al., 2017; Mara, 2018; Abo-Al-Ela, 2019).
Currently, the combination of pyrimethamine (PY) and sulfadiazine (SZ) is the first line of therapy against T. gondii infections (Angel et al., 2020; Secrieru et al., 2020; Shammaa et al., 2021). For congenital toxoplasmosis, spiramycin is used as a prophylactic treatment (Secrieru et al., 2020). For cerebral toxoplasmosis, co-trimoxazole or atovaquone are the most effective drugs recommended for treatment; for T. gondii retinocoroiditis, clindamycin, co-trimoxazole, atovaquone, and prednisone are the most effective drugs (Secrieru et al., 2020). These drugs have serious adverse side effects, impeding their use for all cases of toxoplasmosis (Shiojiri et al., 2019; Angel et al., 2020; Montazeri et al., 2020; Secrieru et al., 2020; Shammaa et al., 2021; Wang et al., 2021). Thus, there is an urgent need to discover new drugs that inhibit T. gondii tachyzoites, the replicative form of the parasite, because of its ability to spread to all organs and its conversion to bradyzoites within tissue cysts (Black and Boothroyd, 2000). Immunosuppression, like in AIDS patients, may result in reactivation of the quiescent tissue cyst causing life-threatening cerebral toxoplasmosis (Luft and Remington, 1992; Luft et al., 1993; Black and Boothroyd, 2000).
Antimalarial compounds such as quinine-based compounds—quinine (Q), dihydroquinine (DHQ), chloroquine (CQ), quinidine (QD), and dihydroquinidine—have been reported to be effective against the human and rodent malaria parasites Plasmodium falciparum and Plasmodium berghei (Polet and Barr, 1968; Brossi et al., 1971; Brossi et al., 1973; Nontprasert et al., 1996; Pukrittayakamee et al., 1997; Sanchez et al., 2008; Achan et al., 2011; Gorka et al., 2013; Prachayasittikul et al., 2013). In addition, quinine has been reported to inhibit T. gondii, Besnoitia jellisoni, and Sarcocystis sp. host cell invasion (Fayer et al., 1972). Interestingly quinine sulfate, a derivative of quinine, exhibited a strong inhibition of skin pathogenic bacteria invasion and internalization of host cells (Wolf et al., 2002; Wolf et al., 2006). Interestingly, DHQ is an impurity often associated with quinine drugs formulations constituting up to 10% and has potent activity against Plasmodium species (Nontprasert et al., 1996). Little is known about the effect of the DHQ effect on T. gondii, which belongs to the same phylum Apicomplexan as Plasmodium spp. and B. jellisoni. Further, the DHQ mechanism of action against T. gondii growth is not known. In this study, we report DHQ inhibition of T. gondii growth, invasion, disruption of mitochondrial membrane, adenosine triphosphate (ATP) production, and induction of elevated reactive oxygen species (ROS) in vitro.
Materials and Methods
Parasites and Host Cell Cultures
hTERT cells (obtained from Silvia Moreno’s Laboratory at the University of Georgia, Athens, GA) were maintained using Dulbecco’s modified Eagle’s medium (DMEM) media supplemented with 1% of penicillin–streptomycin (PS) and Amphotericin B and 10% fetal bovine serum (FBS) (Thermo Fisher Scientific Inc., Waltham, MA, USA). Cells were maintained at 37°C with 5% CO2. The RH-W and RH-RFP (Type I) strains (a gift from Prof. Silvia Moreno) were maintained in DMEM containing 1% PS and 10% FBS or 10% fetal calf serum (FCS) obtained from Sigma-Aldrich (St. Louis, MO, USA).
Inhibition of Intracellular RH-RFP Tachyzoite Growth
To test the anti-T. gondii inhibition of DHQ, an RH-RFP (Type I) T. gondii parasite genetically engineered to express a red fluorescent protein was used (Szajnman et al., 2017). First, hTERT cells (6.0 × 104 cells/ml) were counted and seeded into 96-well plates/100 µl and incubated at 37°C supplemented with 5% CO2 to grow for 24 h according to previous publications (Li et al., 2017; Szajnman et al., 2017). At 24 h, wells were washed with 1× phosphate-buffered saline (PBS) twice, and 100 µl of RH-RFP (6.3 × 104 cells/well) tachyzoites was added to the same 96-well plates and allowed to infect host cells for 3 h at 37°C with 5% CO2 and 95% atmospheric air (Leesombun et al., 2016; Zhang et al., 2019a; Zhang et al., 2019b; Salin et al., 2020; Contreras et al., 2021; Wang et al., 2021). At 3 h, plates were removed from the incubator, and extracellular parasites and the medium were washed off twice with 1× PBS followed by the addition of drugs serially diluted using procedures published by (Salin et al., 2020; Nurkanto et al., 2021; Costa et al., 2021). A volume of 100 µl of DHQ (0, 3.13, 6.25, 12.5, 25, and 50 µM), positive controls (SZ and PY with concentrations of 0, 3.13, 6.25, 12.5, 25, and 50 µM), and negative control (culture media) were added to the designated wells. Plates were read at 24, 48, and 72 h using Tecan 200 F infinite microplate reader set at excitation of 560 nm and emission of 630 nm; the gain was set to 100% optimal with 25 flashes. Plates were read from the top. The percent of parasites growth was calculated using the following formula: (Average control fluorescence wells minus treated fluorescence wells/Average control fluorescence) × 100. From these calculations, the percent inhibition of parasites growth was determined by subtracting parasite growth percent by drugs from 100% growth by the controls (clear culture medium with parasites without drugs). The IC50s were calculated for 24, 48, and 72 h using a non-linear regression approach, where the concentrations were transformed to log10 and plotted against the percent inhibition of T. gondii growth using GraphPad Prism software version 9.0.
Effect of Dihydroquinine Extracellular Pretreatment on Toxoplasma gondii Invasion of hTERT Cells
To evaluate whether DHQ could prevent tachyzoite invasion of host cells, hTERT cells (2 × 105 cells/2 ml) were seeded onto glass coverslips using 6-well plates and allowed to grow to 80% confluency. To perform the invasion assay, compounds DHQ (6.25 and 50 µM), SZ (50 µM), PY (6.25 µM), and PY/SZ (1.56/50 µM) of 100 µl were added to freshly egressed tachyzoites (1.70 × 104 parasites/100 µl) that were purified with Whatman filter of size 3 µm, kept in 1.5-ml Eppendorf tubes, and then incubated for 30 min at 37°C with 5% CO2 with the occasional manual shake. Next, the pretreated extracellular parasites were mixed thoroughly, 100 µl of the mixture was added into 6-well plates containing coverslips with confluent hTERT cells supplemented with 2 ml of fresh medium and allowed to infect the host cells for 1 h, followed by washing away the extracellular parasites using sterilized 1× PBS, performed 3 times, fixed with 100% ethanol, and incubated overnight at 4°C. The next day, the ethanol was taken out followed by three washes with 1× PBS, then stained with hematoxylin for 10 min, washed with 50% ethanol-H2O for 5 min, then stained with Eosin for 5 min, and washed with 50% ethanol-H2O (León-Nava et al., 2016; Muñiz-Hernández et al., 2021). Plates containing stained parasites were visualized for parasitophorous vacuole (PV) formation using the Zeiss 100 phase-contrast fluorescence microscope coupled with an Amscope camera. Five fields were randomly captured per coverslip, and the number of distinct PVs was counted and compared with the control (culture medium). The experiments were performed in duplicate and presented as % PV inhibition plus SD. p < 0.05 was considered as statistically significant to the control and the different drug treatment groups.
Measurement of Reactive Oxygen Species in Toxoplasma gondii
To verify whether DHQ had any oxidative stress effect on parasites, fresh wild-type RH parasites were harvested by passing them through a 27-gauge needle followed by filtration using a 3-µm filter. RH-W parasites (1.60 × 106 parasites/50 µl/well) were seeded into black 96-well plates and treated with H2O2 (500 µM) as a positive control (Ma et al., 2021), ROS buffer was used as a negative control, and DHQ at different concentrations (6.25 and 50 µM) was used as an experimental drug and incubated for 30 min at 37°C with 5% CO2. After the 30-min incubation, 50 µl of H2DCFDA was added, covered with aluminum foil, and incubated for 45 min at 37°C in the dark according to the procedure reported by Charvat and Arrizabalaga (2016). Fluorescence intensities of the wells were measured at excitation 485 and emission 535 nm using a Tecan 200F infinite microplate reader.
Dihydroquinine Effect on Toxoplasma gondii Mitochondrial Membrane Potential (ΔΨm)
For mitochondrial membrane potential measurements, the cationic probe JC-1 was used as previously described by some studies (Charvat and Arrizabalaga, 2016; Syn et al., 2017; Adeyemi et al., 2017; Zhang et al., 2019a; Zhang et al., 2019b). Briefly, freshly purified tachyzoites of 105/50 µl were seeded into black 96-well plates with a clear bottom (Costar, Corning Inc., New York, NY, USA) without host cells followed by the addition of DHQ at concentrations of 6.25, 12.5, and 50 µM of H2O2 (500 µM) as a positive control and the reaction buffer as negative control and incubated for 8 h at 37°C with 5% CO2 according to the manufacturer’s procedure and procedures used in T. gondii by some studies (Charvat and Arrizabalaga, 2016; Zhang et al., 2019a; Zhang et al., 2019b). After the 8-h incubation period (Zhang et al., 2019a; Zhang et al., 2019b), 5 µl of JC-1 was added to both controls and drug-treated wells. The reaction plates were covered with aluminum foil and incubated for 45 min followed by centrifugation at 12°C for 2,000 rpm for 5 min (Charvat and Arrizabalaga, 2016; Zhang et al., 2019a; Zhang et al., 2019b). The supernatant was carefully removed, and 100 µl of the assay buffer (AB) was added to each well and centrifuged again under the same condition. The process was repeated a second time, the wells were refilled with 100 µl of AB, and the parasites’ fluorescence was read at 535/630 nm for the JC-1, J-aggregates and at 485/535 nm for the J-monomers using Tecan 200F infinite microplate reader. The ratio of fluorescence values of J-aggregates to fluorescence values of monomers was calculated using the following formula: RFU J-aggregates/RFU J-Monomers. Images were taken at each treated dose and controls using an EVOS FL fluorescence microscope. For the plate reader data, graphs and statistical differences were obtained using Graph Pad Prism software 9.0.2. A one-way ANOVA was carried out using the Holm–Sidâk multiple-comparisons test with p < 0.05. Means with p < 0.05 were considered as statistically significant relative to controls and the different treated doses/compounds.
Dihydroquinine Effect on Toxoplasma gondii Adenosine Triphosphate Production
To further validate our mitochondrial assay, a modified protocol by Zhang et al. (2019a and 2019b) was used. Fresh extracellular RH-RFP parasites (8.05 × 104 per group) were incubated in a complete medium containing DHQ at concentrations of 6.25, 12.5, and 50 µM or without the drug (medium only with parasites as negative control) and 500 µM of H2O2 as a negative control. After 8 h of incubation, at standard culture condition of 5% CO2 at 37°C, the ATP detection assay kit luminescence (700410; Cayman Chemical, MI, USA) was used to measure the luminescence of samples treated with controls. Experimental drug-treated (DHQ), positive control (H2O2), and negative control (medium with parasites without drugs) were washed twice with PBS, and the pellet was lysed on ice with 100 µl of lysis buffer. Next, 10 µl of the parasite’s lysates were added to 100 µl of ATP detection working solution in each opaque microplate well (Corning Inc., NY, USA). Plates were incubated for 20 min at room temperature according to the ATP detection kit protocol, the cover of the plates was removed, and the luminescence was measured using BioTek Cytation/3 imaging reader with software Gen 5 3.1 (MA, USA). The effect of treatments on the T. gondii ATP luminescence was compared with ATP luminescence of untreated T. gondii population (medium with parasites without experimental drugs or negative controls) and expressed as percentages of these control ATP values. Experiments were conducted in three independent experiments and presented as means plus SD of triplicate trials.
Dihydroquinine Effect on hTERT Mitochondrial Membrane Potential (ΔΨm)
hTERT cells were seeded onto a black 96-well plate at the cell density used for the extracellular parasites’ mitochondrial membrane potential testing as indicated above. At 80% confluence, the medium was removed and washed 3 times with 1× PBS. Drugs were added at similar concentrations used for the parasite mitochondrial membrane potential assay and incubated for 8 h. At 8 h, the JC-1 dye was added, wrapped with aluminum foil, and incubated for 45 min at standard culture conditions. At 45 min, plates were removed from the incubator and centrifuged for 5 min at 12°C for 2,000 rpm. The supernatant was carefully removed, replaced with 100 µl of AB, and centrifuged. The supernatant was discarded one more time and replaced with 100 µl AB and centrifuged, and the supernatant containing JC-1 was carefully removed. Next, 100 µl of the AB was added to the wells, and their fluorescence intensities were recorded at 535/630 nm for the JC-1, J-aggregate form and 485/535 nm for the J-monomers using Tecan 200F infinite microplate reader. The ratio of fluorescence values was determined as stated above. Photomicrographs were taken using EVOS FL fluorescence microscopy. Graphs and statistical differences were obtained using Graph Pad Prism software 9.0.2. p ≤ 0.05 was considered as statistically significant relative to controls and different treated doses.
Cytotoxicity of Dihydroquinine, Sulfadiazine, Pyrimethamine, and Sulfadiazine/Pyrimethamine on Host Cells
CyQuant® NF Cell Proliferation Determination Using hTERT Cells
Exactly 6.0 × 104 cells/well were grown on black 96-well plates at 100 µl for 24 h. Next, at 24 h, medium with dead cells was carefully removed, and the remaining cells were washed three times with 1× PBS and then incubated in 100 µl of drugs at concentrations of 0, 3.13, 6.25, 12.5, 25, and 50 µM for DHQ, SZ, PY, and PY/SZ. Standard culture medium with no phenol red was used as a negative control. At 72 h, NF dye solution was added to wells, covered with aluminum foil, and incubated in standard culture condition for 1 h, and the fluorescence intensity read was at excitation of 485 nm and emission of 535 nm. The percent viability was calculated by subtracting the blank (medium with cells without drugs) from the treated wells. Cell viability was determined using the following formula: (treated/control) × 100.
Statistical Analysis
The IC50s and CC50s were determined using Graph Pad Prism 9.0.2 software. All experiments were performed in duplicate, with each experiment performed in triplicate wells for statistical analysis purposes. A one-way ANOVA was carried out using the Holm–Sidâk multiple-comparisons test on treated samples relative to the controls or in other cases different doses/treatments. A statistically significant difference was reported, where a value of p < 0.05. Also, the selectivity index (SI) was used to determine if the compounds of interest were inhibiting the tachyzoite growth but not toxic at similar concentrations to host cells.
Results
Dihydroquinine Inhibited Toxoplasma gondii RH-RFP Tachyzoite Growth
We assessed the anti-T. gondii activity of DHQ as the compound of interest and compared its effect with the standard drugs SZ and PY in vitro. DHQ inhibited tachyzoite growth in a dose- and time-dependent manner (Table 1). The 50% minimum inhibitory concentration (IC50s) values after 24, 48, and 72 h of interaction between DHQ and parasites were 0.63, 0.68, and 0.0014 µM, respectively. The IC50s for SZ and PY after the same times of interaction were 1.29, 1.55, and 0.95 µM for SZ and 3.19, 3.52, and 2.42 for PY. Surprisingly, at 72 h, DHQ showed an IC50 value in the sub-nanomolar level as compared to the IC50 obtained at 24 and 48 h. Similarly, SZ and PY were more effective at 72 h than 24 and 48 h. Also, of interest was the fact that at concentrations between 6.25 and 50 µM, there was maximum death of T. gondii tachyzoites ranging from 70% to 100% with DHQ, SZ, and PY at different time points selected for the study (Figures 1A–C).
Table 1
| Compounds | IC50 @ 24 h | IC50 @ 48 h | IC50 @ 72 h |
|---|---|---|---|
| DHQ | 0.63 ± 0.0024 | 0.67± 0.27 | 0.0014 ± 0.00 |
| SZ | 1.28 ± 0.33 | 1.55 ± 0.048 | 0.95 ± 0.35 |
| PY | 3.18 ± 0.37 | 3.52 ± 0.27 | 2.42 ± 0.34 |
Mean kinetic IC50s (µM) of DHQ, SZ, and PY on intracellular Toxoplasma gondii tachyzoite growth inhibition.
Data are reported as means IC50s plus SD of three independent experiments performed in triplicate each. hTERT cells (6.0 × 104 cells/ml) were grown for 24 h, and non-adherent cells were washed away. Next, 100 µl of RH-RFP (6.3 × 104 cells/well) tachyzoites was added to wells and incubated for 3 h, followed by 1× phosphate-buffered saline (PBS) wash to remove all the extracellular parasites, leaving only intracellular parasites. Wells were treated with 100 µl volume of compounds (DHQ, SZ, and PY). Parasites fluorescence was recorded for 24, 48, and 72 h, and the 50% minimum inhibitory concentrations of the parasites’ growth were determined. Prior to the IC50s calculations, the concentrations were converted to log and plotted against percent inhibition using a GraphPad Prism. DHQ (dihydroquinine; current compound studied), SZ (sulfadiazine), and PY (pyrimethamine) are the primary known drugs used in combination for the treatment of T. gondii infection. IC50 is the minimum concentration that will inhibit 50% of T. gondii parasites’ growth.
Figure 1
Dihydroquinine Reduces Extracellular Tachyzoite Invasion of Host Cells
We observed that DHQ affected the capacity of tachyzoites to infect hTERT cells in a dose-dependent manner within a short time of 30 min of extracellular exposure to infection of host cells (Figure 2A). Also, we observed that there were fewer PVs formed with a low concentration of DHQ = 6.25 µM and at a high concentration of 50 µM, confirming our inhibition assay that showed that DHQ reduces tachyzoite replication in vitro (Figure 2B). The different doses of DHQ used were significantly different relative to those of other treatments (SZ, PY, and SZ/PY) and control groups (p < 0.05). A similar trend was observed with PY, SZ, and PY combination concentrations tested. However, treatments with 50 µM of SZ were not significantly different from the control p > 0.05 (Figure 2A).
Figure 2
Dihydroquinine Induces Reactive Oxygen Species Generation in Toxoplasma gondii
DHQ is a synthetic organic compound produced during the natural alkaloid (quinine) synthesis as commercial waste with antimalarial properties (Polet and Barr, 1968; Brossi et al., 1971; Brossi et al., 1973; Nontprasert et al., 1996; Pukrittayakamee et al., 1997; Sanchez et al., 2008; Achan et al., 2011; Gorka et al., 2013). Based on the above evidence of DHQ coupled with the remarkable inhibition and anti-invasion data obtained, we tested DHQ against extracellular freshly purified parasites and found that DHQ at 50 µM induced a little higher ROS level in T. gondii tachyzoites in vitro in a concentration-dependent manner (Figure 3). Interestingly, treatment at 6.25 µM of DHQ versus 50 µM of DHQ inhibited parasite invasion significantly (p < 0.01). A similar trend was found with H2O2 (positive control) versus 50 µM of DHQ, and ROS buffer (negative control) versus 6.25 µM of DHQ treatment with (p < 0.01). We also discovered that the total ROS released from tachyzoites as a result of being treated with H2O2 (500 µM) as positive control versus 6.25 µM of DHQ or ROS buffer treatment versus H2O2, or ROS buffer treatment versus 50 µM of DHQ were significantly different with p < 0.02.
Figure 3
Dihydroquinine Causes Mitochondrial Membrane Damage in Toxoplasma gondii But Not of the Host Cells
It has been reported in the literature that a high level of ROS could affect lipids, proteins, DNA, and mitochondrial energy (Lill et al., 2014; Zhao et al., 2015). Based on our previous data of the ROS study, we wanted to decipher whether DHQ affected the T. gondii mitochondrial membrane potential. Here, we used the cationic JC-1 dye to decipher the effect of DHQ on T. gondii tachyzoite mitochondrial membrane potential (ΔΨm). This dye has been used to decipher mitochondrial health in parasites (Charvat and Arrizabalaga, 2016; Zhang et al., 2019a; Zhang et al., 2019b). Surprisingly, we observed that DHQ induced mitochondrial membrane damage in T. gondii tachyzoites in a concentration-dependent manner but not on host cells’ mitochondrial membrane potential at concentrations of 6.25, 12.5, and 50 µM (Figures 4A, B). It was observed that treatment with H2O2 as a positive control compared with 6.25 and 12.5 µM exhibited a statistically significant difference (p < 0.01 and p = 0.01, respectively). Comparison of the negative control (Medium) with 6.25 or 12.5 or 50 µM of DHQ treatment on extracellular parasites showed a significant difference (p < 0.01, p < 0.01, and p = 0.04, respectively). Figure 4C shows a representative image of the DHQ effect on the mitochondrial membrane potential of hTERT cells (host cells). Remarkably, our studies showed that DHQ does not affect host cells’ mitochondrial membrane potential as shown in Figure 4C. A similar result was reported for other mitochondrial membrane potential inhibitors of T. gondii (Zhang et al., 2019a; Zhang et al., 2019b; McPhillie et al., 2020). Thus, the DHQ mechanism of action was solely on the parasite mitochondria and not due to the influence of the hTERT cells.
Figure 4
Dihydroquinine Effect on the Adenosine Triphosphate Level in Toxoplasma gondii
Different doses of DHQ were observed to exert a reduction in T. gondii ATP production in vitro (Figure 4D). Generally, we observed significant statistical differences between the positive (H2O2) control and 6.25, 12.5, or 50 µM (p < 0.01). Similarly, we observed significant statistical differences between the ATP levels of this DHQ with concentrations of 6.25, 12.5, and 50 µM used (p < 0.01). Lastly, the negative controls were significantly different from both experimental drug tested and positive control with p < 0.01.
Dihydroquinine Effect on Host Cell Viability
hTERT Cells
To validate that our inhibition results on parasites were not due to cytopathic effects on the hTERT cells, we tested all compounds’ (DHQ, SZ, and PY) cytotoxicity using serially diluted concentrations of 0, 3.13, 6.25, 12.5, 25, and 50 µM using the same protocol for parasite inhibition assay, with 72-h time exposure to all compounds. We found that treatment with 0.0 to 50 µM of the DHQ compound had no effect on host cell viability (Supplementary Figure 5A).
Also, to prove that DHQ does not alter the morphology of the host cells due to toxicity, we have presented representative images of host cells at selected concentrations (Supplementary Figure 5B). The CC50s were determined to be 209.1, 135.4, and 57.4 µM for DHQ, SZ, and PY, respectively (Table 2).
Table 2
| Compounds | CC50 @ 72 h (LL ± UL) | SI |
|---|---|---|
| DHQ | 209.1 (121.7 ± 501.8) | 149,357.14 |
| SZ | 135.4 (76.9 ± 313.7) | 142.53 |
| PY | 57.34 (42.90 ± 78.79) | 23.69 |
Mean CC50s (µM) of DHQ, SZ, and PY on hTERT cells.
Data are reported as means IC50s plus SD of three independent experiments performed in triplicate each. hTERT cells (6.0 × 104 cells/ml) were grown for 24 h, and non-adherent cells were washed away. Microplate wells were treated with 100-µl volume of compounds (DHQ, SZ, and PY) as described in the anti-parasitic assay for uniformity purposes. The 50% minimum cytotoxic concentrations of the hTERT cells were determined. Prior to the CC50s calculations, the concentrations were converted to log and plotted against the percent viability of host cells using a GraphPad Prism. DHQ (dihydroquinine; current compound studied) SZ (sulfadiazine), and PY (pyrimethamine) are the primary known drugs used in combination for the treatment of Toxoplasma gondii infection. IC50 is the minimum concentration that will inhibit 50% of T. gondii parasites’ growth. CC50 (minimal cytotoxic concentration that will kill 50% of host cells) is presented as triplicate determination (n = 3). SI (selectivity index) is determined by (CC50@72h/IC50@72h) interaction of compounds host cells/parasites. (LL ± UL), where LL is lower limit and UP is upper limit.
Dihydroquinine Selectivity Index
Quinine-based drugs though are still useful in the treatment of malaria and other diseases; their toxicity and other side effects have limited their acceptance in certain countries as the first line of treatment. In this study, we determined the SI of DHQ, which is a derivative of the quinine drug, on the host cell to be 149,357 for hTERT cells. In the standard controls, SZ and PY had their SI values to be 142.53 and 23.69, respectively, for human foreskin fibroblast (hTERT) cells challenged for 72 h in vitro (Table 2).
Discussion
Toxoplasmosis continues to be a major challenge in both veterinary medicine and public health. Globally, more than 30% of the human population and over 35% of domestic and wild felines are infected with T. gondii, respectively (Montoya and Liesenfeld, 2004; Pappas et al., 2009; Robert-Gangneux and Dardé, 2012; Flegr et al., 2014; Montazeri et al., 2020). The consequence of the parasite infection ranges from asymptomatic to life-threatening conditions in both humans and animals (Dubey, 2010; Weiss and Kim, 2011).
Efforts are ongoing to discover novel, safe, and effective vaccines, but none have reached Food and Drug Administration (FDA) approval and commercialization yet, especially for human use (Ducournau et al., 2020). The only option for treating toxoplasmosis in humans has been through antifolate and macrolide drugs (Neville et al., 2015; Shiojiri et al., 2019; Secrieru et al., 2020; Shammaa et al., 2021). However, currently, the use of these drugs is limited geographically, clinically, and socioeconomically (Neville et al., 2015; Shiojiri et al., 2019; Secrieru et al., 2020; Shammaa et al., 2021). Thus, there is an urgent need to discover new compounds or repurposed existing compounds that could be effective, safe, and less costly against parasite infection in humans and even animals. In this study, we investigated DHQ, also known as hydroquinine, for the first time against the RH-RFP (Type I) strain of T. gondii growth and the possible mechanism of action in vitro. DHQ was found to effectively inhibit parasite growth in vitro. This observation agreed with previous studies of this compound on Plasmodium species (Nontprasert et al., 1996). Surprisingly, the IC50s values at 24- to 72-h interactions with parasites in vitro found that DHQ was highly effective than the current drugs, SZ and PY, as positive standards.
It has been reported that the effect of compounds in intracellular parasites may be influenced by first exerting cellular effects on the host cells’ health, causing parasite stress and eventually death (Munera López et al., 2019). To avoid this, it has been suggested that extracellular parasites be treated with compounds prior to infection of host cells to decipher the compound effects on their infectivity or invasion or replication or PV formation (Zhou et al., 2013). We discovered that pretreatment of tachyzoites with DHQ for 30 min followed by infection of host cells for 1 h significantly affected parasite invasion and replication. Uniquely, the anti-invasion activity was dose and compound dependent. Our finding is supported by earlier studies, using quinine, the DHQ parent compound, which showed inhibition of T. gondii, B. jellisoni, and Sarcocystis spp. host cell penetration (Fayer et al., 1972). Additionally, in prokaryotic cells (i.e., bacteria), quinine derivative (quinine sulfate) has been found to block bacteria invasion and internalization (Wolf et al., 2002; Wolf et al., 2006).
To decipher the mechanism of action of DHQ, we performed several experiments using cellular biochemical assays to tease out whether DHQ could have an effect on the mitochondrial membrane potential and the generation of ROS. Noteworthy, we found that DHQ induces elevated ROS production in T. gondii tachyzoites. In the literature, elevated ROS has been shown to contribute to the lethal action of certain antimicrobial, especially the quinolone-based drugs (Zhao et al., 2015). This supports the evidence that compounds that can cause ROS generations to disrupt the mitochondrial detoxifying enzymes such as peroxiredoxin (PRX), superoxide mutase (SOD), and catalase (CAT) act as antioxidants to scavenge the free hydroxyl radicals, superoxide, and hydrogen peroxide (Miller and Britigan, 1997; Vercesi et al., 1998; Odberg-Ferragut et al., 2000; Ding et al., 2000; Kaasch and Joiner, 2000; Son et al., 2001; Kwok et al., 2004).
This conjecture has been reported in Escherichia coli and other parasites to cause abnormality of the cellular repair mechanisms (Dwyer et al., 2007; Hong et al., 2019). Also, compounds that cause elevated ROS generations result in secondary damage, which could severely trigger the continuity of ROS accumulations in the intracellular levels, resulting in the disruption of mitochondrial DNA, nucleic acid, lipid, and protein synthesis (Dwyer et al., 2007; Lavine and Arrizabalaga, 2012; Zhao et al., 2015; Rizk et al., 2021). Thus, we believed that this is one of the means by which DHQ exerts its anti-T. gondii activity.
Mitochondria is an important organelle that supports cellular respiration, production of ATP, fatty acid degradation, nuclear iron–sulfur protein synthesis, DNA synthesis and repairs, tRNA modification, and protein translation (Antico Arciuch et al., 2012; Lill et al., 2014; Syn et al., 2017). Very importantly, in this study with DHQ, we discovered that it disrupted the mitochondrial membrane potential of tachyzoites that were exposed for 8 h in vitro but not host cells. This trend could be attributed to the fact that there is a single mitochondrion in T. gondii (Melo et al., 2000; Zhang et al., 2021). Typically, respiration and phosphorylation processes in T. gondii are carried out in this single mitochondrion (Vercesi et al., 1998; Bhatia-Kissova and Camougrand, 2010; Narendra and Youle, 2011). Since the mitochondria are crucial for the parasite’s energy requirements for survival, growth, movement, replication, and translational activities (Melo et al., 2000; MaCRae et al., 2012; Zhang et al., 2021), damage to this organelle by DHQ could have resulted in the disruption of tachyzoite invasion of host cells, intracellular growth/replication, and eventually death. DHQ effect on the mitochondrial membrane potential was observed to be dose dependent. For example, at concentrations of 6.25, 12.5, and 50 µM of DHQ interaction with RH-wild type tachyzoites (Type I), we found a significant disruption of the mitochondrial membrane potential. This finding supports previous studies by Lavine and Arrizabalaga (2012), which showed that compounds that cause oxidative stress (e.g., monensin) may disrupt both the cell cycle and mitochondrial function of T. gondii tachyzoites by creating autophagy-like cell death in parasites. Furthermore, T. gondii mitochondria are at the center of energy generations, and any change in mitochondrial membrane function affects its ATP production and associated functions (Zhang et al., 2019a; Zhang et al., 2019b). Uniquely, our DHQ treatment decreases T. gondii ATP levels in a dose-dependent manner and was found to significantly differ from both the positive and negative controls. The current finding that DHQ caused a high reduction of ATP levels in RH-RFP tachyzoites confirmed that DHQ could partly be targeting the oxidative phosphorylation of T. gondii parasites. This finding supports several studies that showed that compounds that cause oxidative phosphorylation uncoupling have the tendency to cause disruption of energy metabolism in parasites (Katz, 1986; Frayha et al., 1997; Zhang et al., 2019a; Zhang et al., 2019b). Thus, the reduction of the ATP levels and disruption of mitochondrial membrane potential observed could cause energy shortage and eventually affect parasite invasion, replication, and survival.
Noteworthy, the 50% cytotoxic concentration (CC50) of DHQ on hTERT cells was 209.1 µM (209,100 nM), which makes it less toxic than the gold standard drugs PY and SZ, which were found to have high cytotoxic effects on hTERT cells with CC50s of 135.4 µM (135,400 nM) for SZ and 57.34 µM (57,400 nM) for PY. These cytotoxic values for SZ and PY were within the ranges reported in the literature (Rostamkolaie et al., 2019). Comparatively, our result on the CC50 of SZ obtained agreed with several studies that have reported the CC50s of SZ in various mammalian cells in vitro to be over 1,000 µg/ml (3,995.53 µM) (Leesombun et al., 2016).
Uniquely, the SI of DHQ was over one thousand-fold of what has been reported in SZ and over six thousand-fold more than that of PY. This implies that DHQ is less cytotoxic than both SZ and PY in vitro. This finding indicated that the DHQ anti-T. gondii activities observed were purely due to their potency against the tachyzoite growth in vitro without any cytopathic influence. Several studies have shown that DHQ crosses the blood–brain barrier, has excellent metabolic clearance (Pukrittayakumar et al., 1997; Achan et al., 2011), and thus would have a broad spectrum of inhibition of tachyzoite/bradyzoite growth when successfully developed for the treatment of toxoplasmosis.
Conclusion
DHQ is highly effective in inhibiting the growth, infectivity of host cells, and mitochondrial membrane potential of tachyzoites in vitro in a dose- and time-dependent manner at sub-molar concentrations with negligible effects on human foreskin fibroblast (hTERT) cell viability. DHQ induced high ROS production and induced a decrease of ATP levels in tachyzoites, which explains the disruption of replication, invasion, transcriptional and translational machinery of the parasite, and eventually parasite death due to mitochondrial energy shortage/mitochondrial DNA damage. These findings confirmed that DHQ will be an alternative potent and safe lead compound for the treatment of toxoplasmosis. Our future studies will focus on the medicinal chemistry optimization and evaluation of DHQ and its derivatives in vivo to confirm their safety and efficacy for the treatment of cerebral toxoplasmosis based on its ability to cross the blood–brain barrier.
Funding
DA had internal funding from the Department of Biological Sciences at Alabama State University (ASU) to perform this work.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Author contributions
AH, JA, AN, BR, and DA conceived and supported the idea. AH, JA, and DA carried out the experimental works. AH analyzed the data and drafted the first manuscript under the supervision of DA. DA, BR, and AN revised the drafted manuscript. DA and JA performed the ATP depletion assay and revised the manuscript for resubmission. All authors approved the final manuscript.
Acknowledgments
We wish to thank Distinguished Professor Silvia Moreno at the University of Georgia for her kind gifts of the reagents (host cells and the parasite strains (RH-W and RH-RFP)) as well as her useful suggestions and for reading and correcting the initial manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2022.852889/full#supplementary-material
References
1
Abo-Al-ElaH. G. (2019). Toxoplasmosis and Psychiatric and Neurological Disorders: A Step Toward Understanding Parasite Pathogenesis. ACS Chem. Neurosci.11 (16), 2393–2406. doi: 10.1021/acschemneuro.9b00245
2
AchanJ.TalisunaA. O.ErhartA.YekaA.TibenderanaJ. K.BaliraineF. N.et al. (2011). Quinine, an Old Anti-Malarial Drug in a Modern World: Role in the Treatment of Malaria. Malaria J.10 (1), 144. doi: 10.1186/1475-2875-10-144
3
AdeyemiO. S.MurataY.SugiT.KatoK. (2017). Inorganic Nanoparticles Kill Toxoplasma Gondii via Changes in Redox Status and Mitochondrial Membrane Potential. Int. J. Nanomed.12, 1647. doi: 10.2147/IJN.S122178
4
AngelS. O.VanagasL.RuizD. M.CristaldiC.Saldarriaga CartagenaA. M.SullivanW. J.Jr. (2020). Emerging Therapeutic Targets Against Toxoplasma Gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs. Front. Cell. Infection Microbiol.10, 289. doi: 10.3389/fcimb.2020.00289
5
Antico ArciuchV. G.ElgueroM. E.PoderosoJ. J.CarrerasM. C. (2012). Mitochondrial Regulation of Cell Cycle and Proliferation. Antioxid. Redox Signal.16 (10), 1150–1180. doi: 10.1089/ars.2011.4085
6
Ben-HarariR. R.ConnollyM. P. (2019). High Burden and Low Awareness of Toxoplasmosis in the United States. Postgrad. Med.131 (2), 103–108. doi: 10.1080/00325481.2019.1568792
7
Bhatia-KiššováI.CamougrandN. (2010). Mitophagy in Yeast: Actors and Physiological Roles. FEMS Yeast Res.10 (8), 1023–1034. doi: 10.1111/j.1567-1364.2010.00659.x
8
BlackM. W.BoothroydJ. C. (2000). Lytic Cycle of Toxoplasma Gondii. Microbiol. Mol. Biol. Rev.64 (3), 607–623. doi: 10.1128/MMBR.64.3.607-623.2000
9
BrossiA.UskokovićM.GutzwillerJ.KrettliA. U.BrenerZ. (1971). Antimalarial Activity of Natural, Racemic and Unnatural Dihydroquinine, Dihydroquinidine and Their Various Racemic Analogs in Mice Infected With. Plasmodium Berghei. Experientia27 (9), 1100–1101. doi: 10.1007/BF02138906
10
BrossiA.UskokovićM.GutzwillerJ.KrettliA. U.BrenerZ. (1973). Antimalarial Activity of Racemic 3-Epidihydroquinine, 3-Epidihydroquinidine and Their Various Racemic Analogs in Mice Infected With. Plasmodium Berghei. Experientia29 (3), 367–368. doi: 10.1007/BF01926535
11
CDC. (2021). Retrieved From CDC: Centers for Disease Control Prevention. In: Parasites-Toxoplasmosis (Toxoplasma Infection): Epidemiology and Risk. Available at: https://www.cdc.gov/parasites/toxoplasmosis/epi.html (Accessed 12/31/2021).
12
CharvatR. A.ArrizabalagaG. (2016). Oxidative Stress Generated During Monensin Treatment Contributes to Altered Toxoplasma Gondii Mitochondrial Function. Sci. Rep.6 (1), 1–17. doi: 10.1038/srep22997
13
ContrerasS. M.GanuzaA.CorviM. M.AngelS. O. (2021). Resveratrol Induces H3 and H4K16 Deacetylation and H2A. X Phosphorylation in Toxoplasma Gondii. BMC Res. Notes14 (1), 1–8. doi: 10.1186/s13104-020-05416-4
14
CostaI. N.RibeiroM.Silva FrancoP.da SilvaR. J.de AraújoT. E.MiliánI. C. B.et al. (2021). Biogenic Silver Nanoparticles can Control Toxoplasma Gondii Infection in Both Human Trophoblast Cells and Villous Explants. Front. Microbiol.11, 3645. doi: 10.3389/fmicb.2020.623947
15
DingM.ClaytonC.SoldatiD. (2000). Toxoplasma Gondii Catalase: Are There Peroxisomes in Toxoplasma? J. Cell Sci.113, 2409–2419. doi: 10.1242/jcs.113.13.2409
16
DubeyJ. P. (2010). Toxoplasmosis of Animals and Humans (Boca Raton, Florida: CRC press).
17
DucournauC.MoiréN.CarpentierR.CantinP.HerktC.LantierI.et al. (2020). Effective Nanoparticle-Based Nasal Vaccine Against Latent and Congenital Toxoplasmosis in Sheep. Front. Immunol.11. doi: 10.3389/fimmu.2020.02183
18
DwyerD. J.KohanskiM. A.HayeteB.CollinsJ. J. (2007). Gyrase Inhibitors Induce an Oxidative Damage Cellular Death Pathway in Escherichia Coli. Mol. Syst. Biol.3 (1), 91. doi: 10.1038/msb4100135
19
FayerR.MeltonM. L.SheffieldH. G. (1972). Quinine Inhibition of Host Cell Penetration by Toxoplasma Gondii, Besnoitia Jellisoni, and Sarcocystis Sp. In Vitro. J. Parasitol.58 (3), 595–599. doi: 10.2307/3278212
20
FlegrJ.PrandotaJ.SovičkováM.IsrailiZ. H. (2014). Toxoplasmosis–a Global Threat. Correlation of Latent Toxoplasmosis With Specific Disease Burden in a Set of 88 Countries. PloS One9 (3), e90203. doi: 10.1371/journal.pone.0090203.
21
FrayhaG. J.SmythJ. D.GobertJ. G.SavelJ. (1997). The Mechanisms of Action of Antiprotozoal and Anthelmintic Drugs in Man. Gen. Pharmacol.: Vasc. System28 (2), 273–299. doi: 10.1016/S0306-3623(96)00149-8
22
GajewskiP. D.FalkensteinM.HengstlerJ. G.GolkaK. (2014). Toxoplasma gondii Impairs Memory in Infected Seniors. Brain Behav. Immunol.36, 193–199. doi: 10.1016/j.bbi.2013.11.019
23
GorkaA. P.SherlachK. S.de DiosA. C.RoepeP. D. (2013). Relative to Quinine and Quinidine, Their 9-Epimers Exhibit Decreased Cytostatic Activity and Altered Heme Binding But Similar Cytocidal Activity Versus Plasmodium Falciparum. Antimicrobial Agents Chemother.57 (1), 365–374. doi: 10.1128/AAC.01234-12
24
HongY.ZengJ.WangX.DrlicaK.ZhaoX. (2019). Post-Stress Bacterial Cell Death Mediated by Reactive Oxygen Species. Proc. Natl. Acad. Sci.116 (20), 10064–10071. doi: 10.1073/pnas.1901730116
25
KaaschA. J.JoinerK. A. (2000). Targeting and Subcellular Localization of Toxoplasma Gondii Catalase. Identification of Peroxisomes in an Apicomplexan Parasite. J. Biol. Chem.275, 1112–1118. doi: 10.1074/jbc.275.2.1112
26
KamerkarS.DavisP. H. (2012). Toxoplasma on the Brain: Understanding Host-Pathogen Interactions in Chronic CNS Infection. J. Parasitol. Res.2012, 589295. doi: 10.1155/2012/589295
27
KatzM. (1986). Anthelmintics. Drugs32 (4), 358–371. doi: 10.2165/00003495-198632040-00004
28
KwokL. Y.SchlüterD.ClaytonC.SoldatiD. (2004). The Antioxidant Systems in Toxoplasma Gondii and the Role of Cytosolic Catalase in Defence Against Oxidative Injury. Mol. Microbiol.51 (1), 47–61. doi: 10.1046/j.1365-2958.2003.03823.x
29
LavineM. D.ArrizabalagaG. (2012). Analysis of Monensin Sensitivity in Toxoplasma Gondii Reveals Autophagy as a Mechanism for Drug Induced Death. PloS One7 (7), e42107. doi: 10.1371/journal.pone.0042107
30
LeesombunA.BoonmasawaiS.NishikawaY. (2016). Ethanol Extracts From Thai Plants Have Anti-Plasmodium and Anti-Toxoplasma Activities In Vitro. Acta parasitol.64 (2), 257–261. doi: 10.2478/s11686-019-00036-w
31
León-NavaD.MarcoA.Romero-NúñezE.Luna-NophalA.Bernáldez-SarabiaJ.Sánchez-CamposL. N.et al. (2016). In Vitro Effect of the Synthetic Cal14. 1a Conotoxin, Derived From Conus Californicus, on the Human Parasite Toxoplasma Gondii. Marine Drugs14 (4), 66. doi: 10.3390/md14040066
32
LillR.SrinivasanV.MühlenhoffU. (2014). The Role of Mitochondria in Cytosolic-Nuclear Iron–Sulfur Protein Biogenesis and in Cellular Iron Regulation. Curr. Opin. Microbiol.22, 111–119. doi: 10.1016/j.mib.2014.09.015
33
LiZ. H.LiC.SzajnmanS. H.RodriguezJ. B.MorenoS. N. (2017). Synergistic Activity between Statins and Bisphosphonates Against Acute Experimental Toxoplasmosis. Antimicrob. Agents Chemother.61 (8), e02628–e02616. doi: 10.1128/AAC.02628-16
34
LuftB. J.HafnerR.KorzunA. H.LeportC.AntoniskisD.BoslerE. M.et al. (1993). Toxoplasmic Encephalitis in Patients With the Acquired Immunodeficiency Syndrome. N. Engl. J. Med.329 (14), 995–1000. doi: 10.1056/NEJM199309303291403
35
LuftB. J.RemingtonJ. S. (1992). Toxoplasmic Encephalitis in AIDS. Clin. Infect. Dis.15 (2), 211–222. doi: 10.1093/clinids/15.2.211
36
MaraC. M. (2018). Central Nervous System Infection With Toxoplasma Gondii. Elsevier6. doi: 10.1016/B978-0-444-63849-6.00009-8
37
MacRaeJ. I.SheinerL.NahidA.TonkinC.StriepenB.McConvilleM. J. (2012). Mitochondrial Metabolism of Glucose and Glutamine Is Required for Intracellular Growth of Toxoplasma gondii. Cell Host Microbe12 (5), 682–692. doi: 10.1016/j.chom.2012.09.013
38
MaC. I.TirtorahardjoJ. A.JanS.SchweizerS. S.RosarioS. A.DuY.et al. (2021). Auranofin Resistance in Toxoplasma Gondii Decreases the Accumulation of Reactive Oxygen Species But Does Not Target Parasite Thioredoxin Reductase. Front. Cell. Infection Microbiol.11, 20. doi: 10.3389/fcimb.2021.618994
39
McPhillieM. J.ZhouY.HickmanM. R.GordonJ. A.WeberC. R.LiQ.et al. (2020). Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites. Front. Cell. Infection Microbiol.10, 203. doi: 10.3389/fcimb.2020.00203
40
MeloE. J. L.AttiasM.De SouzaW. (2000). The Single Mitochondrion of Tachyzoites of Toxoplasma Gondii. J. Struct. Biol.130 (1), 27–33. doi: 10.1006/jsbi.2000.4228
41
MillerR. A.BritiganB. E. (1997). Role of Oxidants in Microbial Pathophysiology. Clin. Microbiol. Rev.10, 1–18. doi: 10.1128/CMR.10.1.1
42
MontazeriM.GalehT. M.MoosazadehM.SarviS.DodangehS.JavidniaJ.et al. (2020). The Global Serological Prevalence of Toxoplasma Gondii in Felids During the Last Five Decade–2017): A Systematic Review and Meta-Analysis. Parasites Vectors13 (1), 1–10. doi: 10.1186/s13071-020-3954-1
43
MontoyaJ. G.LiesenfeldO. (2004). Toxoplasmosis. Lancet363 (9425), 1965–1976. doi: 10.1016/S0140-6736(04)16412-X
44
Munera LópezJ.GanuzaA.BogadoS. S.MuñozD.RuizD. M.SullivanW. J.Jr.et al. (2019). Evaluation of ATM Kinase Inhibitor KU-55933 as Potential Anti-Toxoplasma Gondii Agent. Front. Cell. Infection Microbiol.9, 26. doi: 10.3389/fcimb.2019.00026
45
Muñiz-HernándezS.Luna-NophalA.LeónC. T.Domínguez-RamírezL.Patrón-SoberanoO. A.Nava-CastroK. E.et al. (2021). Dehydroepiandrosterone Effect on Toxoplasma Gondii: Molecular Mechanisms Associated to Parasite Death. Microorganisms9 (3), 513. doi: 10.3390/microorganisms9030513
46
NarendraD. P.YouleR. J. (2011). Targeting Mitochondrial Dysfunction: Role for PINK1 and Parkin in Mitochondrial Quality Control. Antioxid. Redox Signaling14 (10), 1929–1938. doi: 10.1089/ars.2010.3799
47
NevilleA. J.ZachS. J.WangX.LarsonJ. J.JudgeA. K.DavisL. A.et al. (2017). Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Sci. Rep.7 (1), 1–32. doi: 10.1371/journal.pone.0090203
48
NgôH. M.ZhouY.LorenziH.WangK.KimT. K.ZhouY.et al. (2017). Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Sci. Rep.7 (1), 11496. doi: 10.1038/s41598-017-10675-6
49
NontprasertA.PukrittayakameeS.KyleD. E.VanijanontaS.WhiteN. J. (1996). Antimalarial Activity and Interactions Between Quinine, Dihydroquinine and 3-Hydroxyquinine Against Plasmodium Falciparum In Vitro. Trans. R. Soc. Trop. Med. Hygiene90 (5), 553–555. doi: 10.1016/S0035-9203(96)90320-X
50
NurkantoA.JeelaniG.SantosH. J.RahmawatiY.MoriM.NakamuraY.et al. (2021). Characterization of Plasmodium Falciparum Pantothenate Kinase and Identification of Its Inhibitors From Natural Products. Front. Cell. Infection Microbiol.11, 101. doi: 10.3389/fcimb.2021.639065
51
Odberg-FerragutC.RenaultJ. P.ViscogliosiE.TourselC.BricheI.EngelsA.et al. (2000). Molecular Cloning, Expression Analysis and Iron Metal Cofactor Characterisation of a Superoxide Dismutase From Toxoplasma Gondii. Mol. Biochem. Parasitol.106, 121– 129. doi: 10.1016/S0166-6851(99)00211-X
52
PappasG.RoussosN.FalagasM. E. (2009). Toxoplasmosis Snapshots: Global Status of Toxoplasma Gondii Seroprevalence and Implications for Pregnancy and Congenital Toxoplasmosis. Int. J. Parasitol.39 (12), 1385–1394. doi: 10.1016/j.ijpara.2009.04.003
53
PoletH.BarrC. F. (1968). Chloroquine and Dihydroquinine. In Vitro Studies of Their Antimalarial Effect Upon Plasmodium Knowlesi. J. Pharmacol. Exp. Ther.164 (2), 380–386.
54
PrachayasittikulV.PrachayasittikulS.RuchirawatS.PrachayasittikulV. (2013). 8-182 Hydroxyquinolines: A Review of Their metal chelating properties and medicinal applications. Drug Des. Devel. Ther.7, 1157. doi: 10.2147/DDDT.S49763
55
PukrittayakameeS.LooareesuwanS.KeeratithakulD.DavisT. M.Teja-IsavadharmP.NagachintaB.et al. (1997). A study of the factors affecting the metabolic clearance of quinine in malaria. Eur. J. Clin. Pharmacol.52 (6), 487–493. doi: 10.1007/s002280050323
56
RizkY. S.Santos-PereiraS.GervazoniL.HardoimD. D. J.CardosoF. D. O.de SouzaC. D. S. F.et al. (2021). Amentoflavone as an Ally in the Treatment of Cutaneous Leishmaniasis: Analysis of Its Antioxidant/Prooxidant Mechanisms. Front. Cell. Infection Microbiol.11, 46. doi: 10.3389/fcimb.2021.615814
57
Robert-GangneuxF.DardéM.-L. (2012). Epidemiology of and Diagnostic Strategies for Toxoplasmosis. Am. Soc. Microbiol., 264–296. doi: 10.1128/CMR.05013-11
58
RostamkolaieL. K.HamidinejatH.JalaliM. R.JafariH.VarziH. N.AbadshapouriM. S. (2019). In Vitro Therapeutic Effect of Hemiscorpius Lepturus Venom on Tachyzoites of Toxoplasma Gondii. J. Parasitic Dis.43 (3), 472–478. doi: 10.1007/s12639-019-01113-7
59
SalinN. H.NoordinR.Al-NajjarB. O.KamarulzamanE. E.YunusM. H.KarimI. Z. A.et al. (2020). Identification of Potential Dual-Targets Anti-Toxoplasma Gondii Compounds Through Structure-Based Virtual Screening and in-Vitro Studies. PloS One15 (5), e0225232. doi: 10.1371/journal.pone.0225232
60
SanchezC. P.SteinW. D.LanzerM. (2008). Dissecting the Components of Quinine Accumulation in Plasmodium Falciparum. Mol. Microbiol.67 (5), 1081–1093. doi: 10.1111/j.1365-2958.2008.06108.x
61
SecrieruA.CostaI. C.O’NeillP. M.CristianoM L (2020). Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis—A Short Bridge Between Two Distant Illnesses. Molecules25 (7), 1574. doi: 10.3390/molecules25071574
62
ShammaaA. M.PowellT. G.BenmerzougaI. (2021). Adverse Outcomes Associated With the Treatment of Toxoplasma Infections. Sci. Rep.11 (1), 1–8. doi: 10.1038/s41598-020-80569-7
63
ShiojiriD.KinaiE.TeruyaK.KikuchiY.OkaS. (2019). Combination of Clindamycin and Azithromycin as Alternative Treatment for Toxoplasma Gondii Encephalitis. Emerg. Infect. Dis.25 (4), 841. doi: 10.3201/eid2504.181689
64
SonE. S.SongK. J.ShinJ. C.NamH. W. (2001). Molecular Cloning and Characterization of Peroxiredoxin From Toxoplasma Gondii. Korean J. Parasitol.39, 133–141. doi: 10.3347/kjp.2001.39.2.133
65
SynG.AndersonD.BlackwellJ. M.JamiesonS. E. (2017). Toxoplasma Gondii Infection is Associated With Mitochondrial Dysfunction in-Vitro. Front. Cell. Infection Microbiol.7, 512. doi: 10.3389/fcimb.2017.00512
66
SzajnmanS. H.GalakaT.LiZ. H.LiC.HowellN. M.ChaoM. N.et al. (2017). In Vitro and In Vivo Activities of Sulfur-Containing Linear Bisphosphonates Against Apicomplexan Parasites. Antimicrobial Agents Chemother.61 (2), e01590–e01516. doi: 10.1128/AAC.01590-16
67
VercesiA. E.RodriguesC. O.UyemuraS. A.ZhongL.MorenoS. N. (1998). Respiration and Oxidative Phosphorylation in the Apicomplexan Parasite Toxoplasma Gondii. J. Biol. Chem.273, 31040–31047. doi: 10.1074/jbc.273.47.31040
68
WangJ. L.ElsheikhaH. M.LiT. T.HeJ. J.BaiM. J.LiangQ. L.et al. (2019). Efficacy of Antiretroviral Compounds Against Toxoplasma Gondii In Vitro. Int. J. Antimicrob. Agents54 (6), 814–819. doi: 10.1016/j.pt.2019.01.005
69
WangD.XingM.El-AshramS.DingY.ZhangX.SangX.et al. (2021). Determination of Lumefantrine as an Effective Drug Against Toxoplasma Gondii Infection–In Vitro and In Vivo Study. Parasitology148 (1), 122–128. doi: 10.1017/S0031182020002036
70
WeissL. M.KimK. (2011). Toxoplasma Gondii: The Model Apicomplexan. Perspectives and Methods (New York: Elsevier).
71
WolfR.BaroniA.GrecoR.DonnarummaG.RuoccoE.TufanoM. A.et al. (2002). Quinine Sulfate and Bacterial Invasion. Ann. Clin. Microbiol. Antimicrobials1 (1), 1–5. doi: 10.1186/1476-0711-1-5
72
WolfR.TufanoM. A.RuoccoV.GrimaldiE.RuoccoE.DonnarummaG.et al. (2006). Quinine Sulfate Inhibits Invasion of Some Bacterial Skin Pathogens. Int. J. Dermatol.45 (6), 661–663. doi: 10.1111/j.1365-4632.2006.02696.x
73
ZhangJ.SiH.LiB.ZhouX.ZhangJ. (2019a). Myrislignan Exhibits Activities Against Toxoplasma Gondii RH Strain by Triggering Mitochondrial Dysfunction. Front. Microbiol.10, 2152. doi: 10.3389/fmicb.2019.02152
74
ZhangJ. L.SiH. F.ShangX. F.ZhangX. K.LiB.ZhouX. Z.et al. (2019b). New Life for an Old Drug: In Vitro and In Vivo Effects of the Anthelmintic Drug Niclosamide Against Toxoplasma Gondii RH Strain. Int. J. Parasitol.: Drugs Drug Resist.9, 27–34. doi: 10.1016/j.ijpddr.2018.12.004
75
ZhangJ.SiH.LvK.QiuY.SunJ.BaiY.et al. (2021). Licarin-B Exhibits Activity Against the Toxoplasma gondii RH Strain by Damaging Mitochondria and Activating Autophagy. Front. Cell. Dev. Biol.9, 684393. doi: 10.3389/fcell.2021.684393
76
ZhaoX.HongY.DrlicaK. (2015). Moving Forward With Reactive Oxygen Species Involvement in Antimicrobial Lethality. J. Antimicrobial Chemother.70 (3), 639–642. doi: 10.1093/jac/dku463
77
ZhouW.QuanJ. H.LeeY. H.ShinD. W.ChaG. H. (2013). Toxoplasma gondii Proliferation Require Down-Regulation of Host Nox4 Expression via Activation of PI3 Kinase/Akt Signaling Pathway. PloS One8 (6), e66306. doi: 10.1371/journal.pone.0066306
Summary
Keywords
dihydroquinine, inhibition, ROS, mitochondria, infectivity, T. gondii
Citation
Huffman AM, Ayariga JA, Napier A, Robertson BK and Abugri DA (2022) Inhibition of Toxoplasma gondii Growth by Dihydroquinine and Its Mechanisms of Action. Front. Cell. Infect. Microbiol. 12:852889. doi: 10.3389/fcimb.2022.852889
Received
11 January 2022
Accepted
14 February 2022
Published
11 May 2022
Volume
12 - 2022
Edited by
Olgica Djurkovic-Djakovic, University of Belgrade, Serbia
Reviewed by
Wanderley De Souza, Federal University of Rio de Janeiro, Brazil; Aleksandra Uzelac, University of Belgrade, Serbia
Updates
Copyright
© 2022 Huffman, Ayariga, Napier, Robertson and Abugri.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Daniel A. Abugri, dabugri@alasu.edu
This article was submitted to Parasite and Host, a section of the journal Frontiers in Cellular and Infection Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.